Work

Supplementary Figure S2 from The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma

Year: 2023

Type: supplementary-materials

Abstract: In vivo effects of crizotinib and PF-06463922 on event-free survival (EFS) in neuroblastoma PDX and xenograft models.

DOI: 10.1158/2159-8290.22531691.v1

Authors: Nicole R. Infarinato, Jin H. Park, Kateryna Krytska, Hannah T. Ryles, Renata Sano, Katherine M. Szigety, Yimei Li, Helen Y. Zou, Nathan V. Lee, Tod Smeal, Mark A. Lemmon, Yael P. Mossé

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362511896

Cites:

Cited by:

Related to: 10